Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00204347 · ClinicalTrials.gov registry record · Phase 4
Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00204347 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT00204347, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of Study A is to evaluate the efficacy of risperidone on the 4 behavioral dimensions of Berderline Personality Disorder (BPD)in an open label trial:mood swings, impulsivity, thing difficulties and disturbed relationships. The secondary objective of this study (Study B)is to validate a self-report measure of clinical symptoms specific to the treatment of patients with BPD, the UAB Borderline Rating Scale(BRS).
Interventions
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00204347
The ClinicalTrials.gov registry entry for NCT00204347 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risperidone is the first listed.
NCT00204347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00204347 about?
NCT00204347 is a clinical study titled "Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder". The objective of Study A is to evaluate the efficacy of risperidone on the 4 behavioral dimensions of Berderline Personality Disorder (BPD)in an open label trial:mood swings, impulsivity, thing difficulties and disturbed relationships. The secondary objective of this study (Study B)is to validate a ...
What is the current status of trial NCT00204347?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2003-07. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00204347?
The interventions under investigation include: risperidone (DRUG).
Who is sponsoring clinical trial NCT00204347?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.